Skip to main content

Advertisement

SpringerLink
Log in

What Are the Most Important New Targets in Breast Cancer?

  • Systemic Therapy (J O’Shaughnessy, Section Editor)
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Breast cancer is a remarkably heterogeneous disease. Data clearly demonstrate the presence of multiple molecular subtypes of breast cancer, and alterations in cell physiology shared by most tumors have been identified. These recent developments in our understanding of the molecular events involved in breast cancer have led to the identification of novel targets as well as anticancer therapies based on these targets. These therapies are referred to as targeted therapy in that the agent has a high specificity for molecules involved in molecular events responsible for the cancer phenotype. This review highlights some of the most promising future targets in breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. American Cancer Society. Breast Cancer Facts & Figures 2009–2010. Atlanta: American Cancer Society.

  2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  3. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

    Article  PubMed  CAS  Google Scholar 

  4. Sorlie T, Perou AM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.

    Article  PubMed  CAS  Google Scholar 

  5. Yu K, Lee CH, Tan PH, et al. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res. 2004;10:5508–17.

    Article  PubMed  CAS  Google Scholar 

  6. Weigelt B, Hu Z, He X, et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005;65:9155–8.

    Article  PubMed  CAS  Google Scholar 

  7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.

    Article  PubMed  CAS  Google Scholar 

  8. •• Hanahan D, Weinberg RA. Hallmarks of Cancer: the Next Generation. Cell 2011, 144: 646-74. This article provides a foundation for understanding targeted agents.

    Article  PubMed  CAS  Google Scholar 

  9. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2neu oncogene. Science. 1987;235:177–82.

    Article  PubMed  CAS  Google Scholar 

  10. • Dawood S, Broglio K, Buzdar A, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol 2009, 28:92–98. This article provides an understanding of the improved prognosis with HER2-targeted agents.

    Article  PubMed  Google Scholar 

  11. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–43.

    Article  PubMed  CAS  Google Scholar 

  12. Lewis Phillips GD, Li G, Duggar DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280–90.

    Article  PubMed  CAS  Google Scholar 

  13. Burris HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate, trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2(HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2010;29:398–405.

    Article  PubMed  Google Scholar 

  14. Adams CW, Allison DE, Flagella K, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother. 2006;55:717–27.

    Article  PubMed  CAS  Google Scholar 

  15. Baselga J, Gelman KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28:1138–44.

    Article  PubMed  CAS  Google Scholar 

  16. Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER2 tyrosine kinase. Cancer Res. 2004;64:3958–65.

    Article  PubMed  CAS  Google Scholar 

  17. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced, ErbB2-positive breast cancer. J Clin Oncol. 1010;28:1301–7.

    Article  Google Scholar 

  18. • Fong PC, Boss DS, Yap TA, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 26:882–93. This article provides an understanding of the mechanism of action of PARP inhibitors.

    Google Scholar 

  19. Turner N, Tutt A, Ashworth A. Hallmarks of “BRCAness”in sporadic cancers. Nat Rev Cancer. 2004;4:814–9.

    Article  PubMed  CAS  Google Scholar 

  20. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer J Clin Oncol 2009; 27 (18 suppl): Abs CRA501

  21. O’Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364:205–14.

    Article  PubMed  Google Scholar 

  22. Zhou J, Wulfkuhle J, Zhang H, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. PNAS. 2007;104:16158–63.

    Article  PubMed  CAS  Google Scholar 

  23. Miller TW, Balko JM, Arteaga C. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29:1–10.

    Article  Google Scholar 

  24. Baselga J, et al. Eur J Cancer Suppl. 2011; 47 (suppl 2): abstract 9LBA

  25. Mayer EL, Krop IE. Advances in targeting Src in the treatment of breast cancer and other solid malignancies. Clin Cancer Res. 2010;16:3526–32.

    Article  PubMed  CAS  Google Scholar 

  26. Gucalp A, Sparano JA, Caravelli J, et al. Phase II trial of saracatinib (AZDO530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer 2011; May 3 (epub ahead of print).

  27. Mayer E, Baurain J, Sparano J, et al. Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA 180088. J Clin Oncol 2009; 27:15s (suppl; abstr 1011).

  28. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4–6.

    Article  PubMed  CAS  Google Scholar 

  29. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997;57:963–9.

    PubMed  CAS  Google Scholar 

  30. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.

    Article  PubMed  CAS  Google Scholar 

  31. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3239–47.

    Article  PubMed  CAS  Google Scholar 

  32. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth dactor receptor2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–60.

    Article  PubMed  CAS  Google Scholar 

  33. O’Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of overall survival data from 3 randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol. 2010;28:1005.

    Article  Google Scholar 

  34. Bergh J, Greial R, Voytko N, et al. Sunitinib (SU) in combination with docetaxel (D) vs D alone for the first-time treatment of advanced breast cancer (ABC). J Clin Oncol 2010: 28: 7s(abs LBA 1010)

  35. Crown J, Dieras V, Staroslawska E, et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 2010; 28: 7s(abs LBA 1011)

  36. Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer. 2011;11:273.

    Article  CAS  Google Scholar 

  37. Gradishar WJ, Kaklamani V, Prasad Sahoo T et al. A double-blind, randomized, placebo-controlled, Phase IIb study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer (BC). Cancer Res 2009: 69 (24 suppl): Abstract 44.

  38. Baselga J; Roche H, Costa F, et al. SOLTI-0701: A multinational double-blind, randomized Phase IIB study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). Cancer Res 2009: 69 (24 suppl): Abstract 45.

  39. Hudis C, Tauer KW, Hermann RC, et al. Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV). J Clin Oncol 2011; 29: (suppl) abstract 1009.

    Google Scholar 

  40. Papa V, Gliozzo B, Clark GM, et al. Insulin-like growth factor-1 receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res. 1993;53:3736–40.

    PubMed  CAS  Google Scholar 

  41. Zhang H, Yee D. Type 1 Insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res. 2005;12:10123–7.

    Google Scholar 

  42. Kaufman PA, Ferrero JM, Bourgeois H, et al. A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res 2010: Abstract S1-4

  43. Kim LS, Kim JH. Heat shock protein as molecular targets for breast cancer therapeutics. J Breast Cancer. 2011;14(3):167–74.

    Article  PubMed  Google Scholar 

  44. Modi S, Sugarman S, Stopeck A, et al. Phase II trial of the HSP90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC). J Clin Oncol 2008; 26: 47s (abstract 1027).

  45. Mehnert JM, Kelly WK. Histone deacetylase inhibitors: biology and mechanism of action. Cancer J. 2007;13:23–9.

    Article  PubMed  CAS  Google Scholar 

  46. Luu TH, Morgan RJ, Leong L, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California cancer consortium study. Clin Cancer Res. 2008;14:7138–42.

    Article  PubMed  CAS  Google Scholar 

  47. Munster PN, Thurn KT, Thomas S, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104:1828–35.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

M. Cianfrocca has received honoraria for her work on the Advisory Boards of Genentech and Celgene and has had travel expenses covered by these companies as well.

Author information

Authors and Affiliations

  1. Breast Cancer Program, Banner MD Anderson Cancer Center, 2946 E. Banner Gateway Drive, Suite 450, Gilbert, AZ, 85234, USA

    Mary Cianfrocca

Authors
  1. Mary Cianfrocca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary Cianfrocca.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cianfrocca, M. What Are the Most Important New Targets in Breast Cancer?. Curr Breast Cancer Rep 4, 83–88 (2012). https://doi.org/10.1007/s12609-011-0068-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-011-0068-y

Keywords

Search

Navigation